Advertisement
BNTX vs NVAX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BNTX is a Hold and NVAX is a Hold.
BNTX in downward trend: 10-day moving average crossed below 50-day moving average on October 01, 2026
The 10-day moving average for BNTX crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BNTX as a result. In 71 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
BNTX moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for BNTX entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BNTX's RSI Indicator exited the oversold zone, 20 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 50-day moving average for BNTX moved above the 200-day moving average on September 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +0.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNTX advanced for three days, in 185 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
BNTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.232) is normal, around the industry mean (26.782). P/E Ratio (161.759) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.046) is also within normal values, averaging (9.059). BNTX's Dividend Yield (0.013) is considerably higher than the industry average of (0.000). P/S Ratio (7.764) is also within normal values, averaging (437.542).
The Tickeron Seasonality Score of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. BNTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NVAX in downward trend: price may drop because broke its higher Bollinger Band on October 09, 2026
NVAX broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 45 similar instances where the stock broke above the upper band. In 40 of the 45 cases the stock fell afterwards. This puts the odds of success at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for NVAX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 21 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 21, 2026. You may want to consider a long position or call options on NVAX as a result. In 63 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for NVAX just turned positive on October 05, 2026. Looking at past instances where NVAX's MACD turned positive, the stock continued to rise in 33 of 45 cases over the following month. The odds of a continued upward trend are 73%.
The 50-day moving average for NVAX moved above the 200-day moving average on September 24, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +1.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVAX advanced for three days, in 183 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 101 of 123 cases where NVAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. NVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (32.467) is normal, around the industry mean (26.782). P/E Ratio (3.140) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (3.759) is also within normal values, averaging (437.542).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
BNTX | NVAX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 65 | 91 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 2 Undervalued | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 93 | 100 | |
PRICE GROWTH RATING 1..100 | 71 | 35 | |
P/E GROWTH RATING 1..100 | 1 | 13 | |
SEASONALITY SCORE 1..100 | 11 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BNTX's Valuation (2) in the null industry is significantly better than the same rating for NVAX (75) in the Biotechnology industry. This means that BNTX’s stock grew significantly faster than NVAX’s over the last 12 months.
BNTX's Profit vs Risk Rating (100) in the null industry is in the same range as NVAX (100) in the Biotechnology industry. This means that BNTX’s stock grew similarly to NVAX’s over the last 12 months.
BNTX's SMR Rating (93) in the null industry is in the same range as NVAX (100) in the Biotechnology industry. This means that BNTX’s stock grew similarly to NVAX’s over the last 12 months.
NVAX's Price Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for BNTX (71) in the null industry. This means that NVAX’s stock grew somewhat faster than BNTX’s over the last 12 months.
BNTX's P/E Growth Rating (1) in the null industry is in the same range as NVAX (13) in the Biotechnology industry. This means that BNTX’s stock grew similarly to NVAX’s over the last 12 months.
| BNTX | NVAX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 74% | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 72% | 2 days ago 88% |
| Momentum ODDS (%) | 2 days ago 72% | 2 days ago 76% |
| MACD ODDS (%) | N/A | 2 days ago 73% |
| TrendWeek ODDS (%) | 2 days ago 77% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 76% | 2 days ago 82% |
| Advances ODDS (%) | 12 days ago 69% | 18 days ago 79% |
| Declines ODDS (%) | 3 days ago 78% | 9 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 75% | 2 days ago 89% |
| Aroon ODDS (%) | 2 days ago 76% | 2 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BNTX’s FA Score shows that 2 FA rating(s) are green while NVAX’s FA Score has 1 green FA rating(s).
- BNTX’s FA Score: 2 green, 3 red.
- NVAX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BNTX’s TA Score shows that 5 TA indicator(s) are bullish while NVAX’s TA Score has 5 bullish TA indicator(s).
- BNTX’s TA Score: 5 bullish, 5 bearish.
- NVAX’s TA Score: 5 bullish, 4 bearish.
Price Growth
BNTX (@Biotechnology) experienced а -2.02% price change this week, while NVAX (@Biotechnology) price change was +16.44% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -19.76%.
Reported Earning Dates
BNTX is expected to report earnings on Nov 03, 2026.
NVAX is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-8.57% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement